Hycor Biomedical Inc. on Tuesday said it has received Food andDrug Administration approval to market its PyloragenHelicobacter pylori tests.

H. pylori is a bacterium associated with chronic gastritis andpeptic ulcers. It is implicated in gastric cancer.

Hycor (NASDAQ:HYBD) said its serological test producesresults faster than any other FDA-approved product. In recentmonths, Whittaker Bioproducts Inc., Enteric Products Inc.,Biomerica Inc., Meridian Diagnostics Inc. and Quidel Corp. haveall announced marketing plans for H. pylori tests.

The Hycor product will be distributed in the United States byBaxter Scientific Products and Curtin Matheson Scientific.International partnerships are being explored.

Hycor stock closed up 38 cents at $4.88 on Tuesday.

(c) 1997 American Health Consultants. All rights reserved.